OQRO

Daily notes / October 15, 2026

Psyence Labs filed an amended ownership report on Psyence Biomedical

Written by a model from the facts OQRO holds and checked against them, sentence by sentence of . Published . 2 min read.

Tall office buildings around Trinity Church in lower Manhattan seen from above, with the church spire between the towers.
Skyscrapers around Trinity Church, New York, 1905. Photo: Detroit Publishing Company (scan by the New York Public Library), Public domain (scan of a 1905 photograph, New York Public Library Digital Collections). Original

The short answer

Psyence Labs Ltd. filed a Schedule 13D/A on Oct 15, 2026, reporting 2,643,659 shares, 49.75% of the class of Psyence Biomedical (PBM). The filing reports ownership, not a specific share purchase or its timing. Other ownership filings, short-interest data, press headlines and share-price movements are also on record, but they do not explain the filing or price changes.

What did Psyence Labs report?

Psyence Labs Ltd. filed a Schedule 13D/A on Oct 15, 2026. The report lists 2,643,659 shares, 49.75% of the class of Psyence Biomedical (PBM).

A Schedule 13D/A is an ownership filing. The figures report the stake but do not say when shares were bought.

What other ownership filings are on record?

In the 180 days to Oct 15, 2026, Schedule 13D and 13G filings on Psyence Biomedical included an Oct 5, 2026 filing by AdvisorShares Trust. That filing reported AdvisorShares Trust then owned 6.8% of PBM as a passive investor.

The AdvisorShares Trust filing is separate from the report by Psyence Labs Ltd. The facts provided do not describe a connection between the filings.

What did short-interest data show?

FINRA short interest for PBM on the settlement date of Sep 30, 2026 was 26,839 shares, -44.34% on the previous report, and about 1 days of average volume.

Short-interest data is separate from the Schedule 13D/A. It does not establish when Psyence Labs acquired shares or explain the reported ownership stake.

What news and share-price context was listed?

Finnhub listed the Yahoo headline “Psyence BioMed Partners with DEA-Registered Benuvia Operations to Establish U.S. Manufacture of Pharmaceutical-Grade Ibogaine”, dated Oct 5, 2026. It also listed the Yahoo headline “Psyence BioMed Announces Exclusive U.S. Ibogaine Licence for Texas Ibogaine Research Corporation”, dated Sep 28, 2026. The headlines are listed as published by the outlets; OQRO has not checked them and does not summarise the articles.

PBM closed at $5.48 on Oct 1, 2026, the last session on or before the filing date. From Sep 1, 2026 to Oct 1, 2026, the close moved from $4.37 to $5.48, a change of +25.4%. From Oct 1, 2026 to Oct 15, 2026, the close moved from $5.48 to $4.32, a change of −21.2%.

What this does not tell you?

A Schedule 13D or 13G is an ownership filing, not a trade; it does not say when shares were bought. The filing does not explain share-price movements, and other news can move a price.

The press items are headlines listed as published by the outlets; OQRO has not checked them and does not summarise the articles. Share-price movements are context only. This describes public filings and is not investment advice. More public-record context is available at Psyence Biomedical on OQRO.

Sources

A model wrote this page from the facts OQRO holds; every number, date, name and link in it was checked against those facts before publication, and a text that failed the check was not published. It describes what was filed, not why, and it is not investment advice. How OQRO treats data

Explore the data

More daily notes